Format

Send to

Choose Destination
Trends Pharmacol Sci. 2019 Jun;40(6):367-377. doi: 10.1016/j.tips.2019.04.003. Epub 2019 May 8.

Novel Approaches to Persistent Pain Therapy.

Author information

1
Institute of Clinical Pharmacology, Pharmazentrum Frankfurt, Zentrum für Arzneimittelforschung, Entwicklung, und Sicherheit (ZAFES), University Hospital of Goethe-University, 60590 Frankfurt am Main, Germany.
2
Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Translational Medicine and Pharmacology (TMP), Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
3
Institute of Clinical Pharmacology, Pharmazentrum Frankfurt, Zentrum für Arzneimittelforschung, Entwicklung, und Sicherheit (ZAFES), University Hospital of Goethe-University, 60590 Frankfurt am Main, Germany; Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Translational Medicine and Pharmacology (TMP), Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany. Electronic address: geisslinger@em.uni-frankfurt.de.

Abstract

Persistent and neuropathic pain affects >15% of the global population. Apart from being an individual burden to the patient, persistent pain causes considerable subsequent costs in global healthcare systems. Despite the efforts of pharmaceutical companies to develop novel analgesics, pharmacological options for the therapy of persistent and/or neuropathic pain are limited. We discuss here novel approaches to persistent pain therapy that are independent of classical target-based drug discovery, focusing on individualized diagnostic technologies, improvement of existing therapies, and expansion of current pharmacological treatments and future techniques that may broaden pharmacological options for the individual treatment of persistent pain in patients.

KEYWORDS:

CRISPR; analgesic; iPSC; monoclonal antibody; opioid; pain

PMID:
31078322
DOI:
10.1016/j.tips.2019.04.003

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center